Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

LY3537021

INVESTIGATIONAL

Selective long-acting GIP receptor agonist

5
graded results
0
ongoing records
5
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 5Very low evidence 0

LY3537021 is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Chemotherapy-induced nausea and vomiting; Subcutaneous injection; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
LY3537021 INVESTIGATIONAL
appetite-intake Decrease
Low evidence

The selective GIPR agonist LY3537021 produced dose-dependent weight loss in phase 1 whose apparent mode of action is appetite suppression, inferred from spontaneous...

Long-acting GIPR agonist LY3537021 reduces body weight and fasting glucose in T2D: precli... Source
Full findingThe selective GIPR agonist LY3537021 produced dose-dependent weight loss in phase 1 whose apparent mode of action is appetite suppression, inferred from spontaneous adverse events of decreased appetite/early satiety; the formal appetite VAS showed no conclusive effect and energy intake was not formally measured.
PopulationPhase 1 (incl. T2D MAD), humans
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
LY3537021 INVESTIGATIONAL
glycaemic Mixed
Low evidence

Transient reductions in fasting glucose in T2D participants that were not sustained vs placebo by day 29.

Long-acting GIPR agonist LY3537021 reduces body weight and fasting glucose in T2D: precli... Source
PopulationPhase 1 MAD, T2D participants (NCT04586907); placebo comparator
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
LY3537021 INVESTIGATIONAL
pharmacology Not directional
Low evidence

In-vitro potency greater than native GIP, GIPR-selective; half-life ~12 days supporting once-weekly dosing; no delay in gastric emptying after single SC dose.

Long-acting GIPR agonist LY3537021 reduces body weight and fasting glucose in T2D: precli... Source
PopulationIn vitro, rats, phase 1 humans
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsnative GIP; placebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
LY3537021 INVESTIGATIONAL
Stomach and gut No change
Low evidence

Well tolerated with infrequent gastrointestinal adverse events.

Long-acting GIPR agonist LY3537021 reduces body weight and fasting glucose in T2D: precli... Source
PopulationPhase 1 SAD/MAD N=85; placebo comparator
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
LY3537021 INVESTIGATIONAL
weight-loss Decrease
Low evidence

Selective GIPR agonist monotherapy induced dose-dependent body-weight reduction in a phase 1 MAD study, persisting after last dose.

Long-acting GIPR agonist LY3537021 reduces body weight and fasting glucose in T2D: precli... Source
PopulationPhase 1 SAD/MAD RCT (NCT04586907), Singapore; N=85 (SAD n=47, MAD n=38) healthy + T2D; baseline BMI 25.9-27.0; placebo comparator
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo